EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain.

doi:10.1177/10781552221085253

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Jun 2023

Delgado Sillero Irene, Lopetegui Lia Nerea, Sánchez Cousido Luis Felipe, Rojas Piedra Mariam, Távara Silva Blanca, Garrido Onecha Maria Luisa, Medina Valdivieso Soledad, Alonso Horcajo Nieves, Díez Tascón Cristina, López González Ana, Castañón López Carmen, Pedraza Lorenzo Manuela, García Palomo Andrés, Martín Vicente, Diz Tain Pilar

Abstract excerpt

INTRODUCTION: 10-16% of non-small cell lung cancer (NSCLC) cases have the epidermal growth factor receptor (EGFR) amplified and/or mutated. Studies show that EGFR tyrosine kinase inhibitors (TKIs) significantly prolong progression-free survival (PFS) in patients with advanced NSCLC compared to those treated with platinum-based chemotherapy (CT) doublets. Our aim is to perform a real-world survival analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Hospitals

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Spain

Source

Open in PubMed

Identifiers

PMID: 35306915
DOI: 10.1177/10781552221085253

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain.PMID 35306915Read ↗

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.Semantic proximity Read ↗

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.Semantic proximity Read ↗

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.Semantic proximity Read ↗

Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations.Semantic proximity Read ↗

The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.Semantic proximity Read ↗

Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017-2020.Semantic proximity Read ↗

Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.Semantic proximity Read ↗

Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.Semantic proximity Read ↗

[Management of EGFR mutated non-small cell lung carcinoma patients].Semantic proximity Read ↗

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.Semantic proximity Read ↗

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.